{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:22:37Z","timestamp":1794684157372,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy (NAC) combined with human epidermal growth factor receptor 2 (HER2)-targeted agents is the mainstay of treatment of HER2-positive (HER2\u2009+) breast cancer (BC). We investigated intrinsic subtypes and clinicopathological features as predictors of outcomes of NAC in HER2\u2009+\u2009early-stage BC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of 186 consecutive patients with early-stage HER2\u2009+\u2009BC, as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization, who received NAC plus HER2-targeted agents, 167 with an available biopsy specimen were eligible for inclusion. Intrinsic subtypes were determined by MammaPrint and Blueprint (MP\/BP). Whole-slide images of HER2 IHC staining were used to evaluate intensity of HER2 staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MP\/BP subtype was determined for 124 patients: Luminal-A, 17 patients; Luminal-B, 23 patients; HER2, 76 patients; and Basal, 8 patients. Pathological complete response (pCR) rate was significantly higher in HER2 than in non-HER2 cases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). High-intensity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and BP-determined HER2 intrinsic subtype (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024) were identified as independent factors for pCR prediction. Neither Luminal subtype was found in IHC estrogen receptor (ER)-negative patients; however, 54.3% of IHC ER-positive patients had HER2 subtype. Five-year distant disease\u2013free survival by MP\/BP subtype was Luminal-A, 92.3%; Luminal-B, 81.6%; HER2, 84.0%; and Basal, 80.0%. Of the 23 patients whose subtypes were compared before and after surgery, 10 had a change in subtype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High HER2 intensity and HER2 intrinsic subtype could be a means for predicting achievement of pCR. The findings indicate the essential role of MP\/BP subtyping in the treatment of HER2\u2009+\u2009BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>UMIN000049957.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15133-5","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:16:59Z","timestamp":1762262219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8486-6475","authenticated-orcid":false,"given":"Sayumi","family":"Imamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5129-9597","authenticated-orcid":false,"given":"Kiyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3729-1520","authenticated-orcid":false,"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-042X","authenticated-orcid":false,"given":"Chie","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"15133_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","volume":"30","author":"N Wolmark","year":"2001","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96\u2013102. https:\/\/doi.org\/10.1093\/oxfordjournals.jncimonographs.a003469.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"15133_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","volume":"97","author":"D Mauri","year":"2005","unstructured":"Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188\u201394. https:\/\/doi.org\/10.1093\/jnci\/dji021.","journal-title":"J Natl Cancer Inst"},{"key":"15133_CR3","doi-asserted-by":"publisher","first-page":"e066381","DOI":"10.1136\/bmj-2021-066381","volume":"375","author":"F Conforti","year":"2021","unstructured":"Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomized clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381. https:\/\/doi.org\/10.1136\/bmj-2021-066381.","journal-title":"BMJ"},{"key":"15133_CR4","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res"},{"key":"15133_CR5","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.023.","journal-title":"Eur J Cancer"},{"key":"15133_CR6","first-page":"1045","volume":"10","author":"J Kreutzfeldt","year":"2020","unstructured":"Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res. 2020;10:1045\u201367.","journal-title":"Am J Cancer Res"},{"key":"15133_CR7","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.ctrv.2021.102286","volume":"100","author":"E Hamilton","year":"2021","unstructured":"Hamilton E, Shastry M, Schiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102286.","journal-title":"Cancer Treat Rev"},{"key":"15133_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1602253.","journal-title":"N Engl J Med"},{"key":"15133_CR9","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1245\/s10434-014-3908-y","volume":"21","author":"P Whitworth","year":"2014","unstructured":"Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, et al. Chemosensitivity predicted by blueprint 80-gene functional subtype and MammaPrint in the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol. 2014;21:3261\u20137. https:\/\/doi.org\/10.1245\/s10434-014-3908-y.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"15133_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdv106","volume":"26","author":"S Gourgou-Bourgate","year":"2015","unstructured":"Gourgou-Bourgate S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, et al. Guidelines for time-to-event and point definitions in breast cancer trials results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in cancer trials). Ann Oncol. 2015;26(5):873\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdv106.","journal-title":"Ann Oncol"},{"key":"15133_CR11","doi-asserted-by":"publisher","first-page":"e23053","DOI":"10.1097\/MD.0000000000023053","volume":"99","author":"JH Choi","year":"2020","unstructured":"Choi JH, Jeon CW, Kim YO, Jung S. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer. Medicine (Baltimore). 2020;99:e23053. https:\/\/doi.org\/10.1097\/MD.0000000000023053.","journal-title":"Medicine (Baltimore)"},{"key":"15133_CR12","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-06-3022","volume":"13","author":"L Arnould","year":"2007","unstructured":"Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, et al. Pathologic complete response to trastuzumab-based neoadjuvant chemotherapy is related to the level of HER-2 amplification. Clin Cancer Res. 2007;13:6404\u20139.","journal-title":"Clin Cancer Res"},{"key":"15133_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ijc.28660","volume":"135","author":"EM Fuchs","year":"2013","unstructured":"Fuchs EM, K\u00f6stler WJ, Horvat R, Hudelist G, Kubista E, Attems J, et al. High-level ERBB2 gene amplification is associated with a particularly short time-to metastasis, but results in a ahigh rate of complete response once trastuzumab-based therapy is offered in the metastatic setting. Int J Cancer. 2013;135:224\u201331. https:\/\/doi.org\/10.1002\/ijc.28660.","journal-title":"Int J Cancer"},{"key":"15133_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ejca.2006.11.019","volume":"43","author":"R Giuliani","year":"2007","unstructured":"Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, et al. Phosphorylated HER-2 tyrosine kinase and HER2\/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer. 2007;43:725\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2006.11.019.","journal-title":"Eur J Cancer"},{"issue":"10","key":"15133_CR15","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"G Otto Metzger","year":"2021","unstructured":"Otto Metzger G, Giuseppe V, Shayna S, Lorenzo T, Denise AY, Ingrid AM, et al. Impactof HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer\u202f: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021;11(10):2474\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1557.","journal-title":"Cancer Discov"},{"key":"15133_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","volume":"18","author":"A Llombart-Cussac","year":"2017","unstructured":"Llombart-Cussac A, Cortes J, Pare L, Galv\u00e1n P, Bermejo B, Mart\u00ednez N, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18:545\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(17)30021-9.","journal-title":"Lancet Oncol"},{"key":"15133_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"key":"15133_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im Y, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(16)00163-7.","journal-title":"Lancet Oncol"},{"key":"15133_CR19","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"},{"key":"15133_CR20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372. https:\/\/doi.org\/10.1056\/NEJMoa052306.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15133-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:03:27Z","timestamp":1762308207000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15133"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15133-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study was conducted under the umbrella of \u201cA multicenter cohort study to build better breast cancer care and consensus based on the real-world evidence (KBCSG-TR 1316), which was approved by the Central Ethics Committee of NHO Osaka National Hospital (Osaka, Japan) and registered at the UMIN-CTR (UMIN000049957, on January 3rd, 2023). The study was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived given the retrospective noninvasive nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent to publish the study data was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Masuda N reports receiving honoraria (e.g. lecture fees) from AstraZeneca, Chugai, Daiichi Sankyo, Eli-Lilly, and Pfizer; research funding to institution from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli-Lilly, Gilead Sciences, Kyowa-Kirin, MSD, Novartis, Ono-Pharma, and Pfizer; being a member of board of directors for Japanese Breast Cancer Society (JBCS), Japan Society of Clinical Oncology (JSCO), and Japan Breast Cancer Research Group Association (JBCRG). All other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1707"}}